Home › Treatment Guides › Mounjaro Eligibility UK 2026
Mounjaro Eligibility UK 2026: NHS Cohorts, Private Criteria, BMI Thresholds & Who Qualifies
Don’t Qualify for NHS Mounjaro? Slinic Provides Private Access From £139
GPhC No. 1033729 · NHS-contracted · BMI 30+ or 27+ with a qualifying condition · Fixed 2026 prices · Same-day prescriber review · Next-day delivery
- ✅ Private eligibility: BMI 30+ or 27+ with T2D, hypertension, high cholesterol, CVD, or sleep apnoea
- ✅ Mounjaro 2.5mg £139 · 5mg £165 · 7.5mg £225 · 10mg £255 · 12.5mg £275 · 15mg £285
- ✅ Free starter pack · Free monthly check-ins · £4.99 next-day delivery · No subscription
- ✅ No waiting list · No GP referral needed · Prescriber review same working day
Mounjaro eligibility in the UK is one of the most searched and most misunderstood topics in weight management in 2026. The NHS rollout is phased, the criteria are strict, and they changed again on 23 June 2026. Private eligibility is simpler and broader — but the rules still matter for safety and GPhC compliance. This guide covers everything: the current NHS cohort criteria, how private prescribing works, ethnic BMI adjustments, contraindications, the T2D pathway, and what to do if you are not yet eligible.
Quick Answer: Do You Qualify for Mounjaro?
| Route | BMI requirement | Conditions required | Waiting time | Cost |
|---|---|---|---|---|
| Private — Slinic | 30+ (or 27+ with condition) | None required at BMI 30+. One qualifying condition at BMI 27–29.9. | None — 24-hour dispatch | From £139/month fixed |
| NHS Cohort 1 (primary care) | 40+ (37.5+ with ethnic adjustment) | At least 4 of 5: T2D, hypertension, dyslipidaemia, CVD, sleep apnoea | Depends on GP practice opting in — may be immediate or months | Free on prescription |
| NHS Cohort 2 (from 23 Jun 2026) | 35–39.9 (32.5–37.4 with ethnic adjustment) | At least 4 of 5 same conditions as Cohort 1 | Variable — GP practice must opt in to QOF pathway | Free on prescription |
| NHS Cohort 3 (from Apr 2027) | 40+ (37.5+ with ethnic adjustment) | At least 3 of 5 qualifying conditions | From April 2027 — not yet active | Free on prescription |
| NHS Tier 3 specialist services | BMI 35+ with comorbidity (varies by ICB) | Varies by ICB — typically BMI 35+ with T2D or CVD | 12–36 months typically — see NHS guide | Free on prescription |
| QOF T2D pathway (from Apr 2026) | BMI 35+ with T2D and ≥1 other condition (NICE TA1026) | T2D plus ≥1 qualifying condition — GP practice must adopt QOF pathway | Varies by GP practice | Free on prescription |
Private Mounjaro Eligibility — The Full Criteria
Private prescribing of Mounjaro is governed by the MHRA licence, NICE guidance (TA1026), and the professional judgment of the prescribing clinician. At Slinic, the eligibility criteria are:
Minimum BMI for private Mounjaro
- BMI 30 or above — eligible regardless of co-morbidities
- BMI 27–29.9 — eligible with at least one qualifying weight-related health condition
- BMI below 27 — not eligible for Mounjaro under any route
Qualifying weight-related conditions (one required at BMI 27–29.9)
- Type 2 diabetes
- Hypertension (high blood pressure — diagnosed, not just elevated readings)
- Dyslipidaemia (high cholesterol — diagnosed)
- Established cardiovascular disease (heart attack, stroke, angina, heart failure history)
- Obstructive sleep apnoea (diagnosed, with or without CPAP)
- Non-alcoholic fatty liver disease (NAFLD/NASH) — less commonly cited but clinically supported
Ethnic BMI adjustment for private prescribing
For individuals from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds, the NICE-recommended BMI thresholds are reduced by 2.5 kg/m²:
- Standard BMI 30 threshold → 27.5 for these groups
- Standard BMI 27 threshold → 24.5 for these groups
This adjustment reflects higher cardiometabolic risk at lower BMI in these populations — a clinically established phenomenon supported by NICE and the World Health Organisation. Your Slinic prescriber applies this adjustment automatically at assessment.
NHS Mounjaro Eligibility 2026 — The Phased Rollout Explained
NICE recommended tirzepatide (Mounjaro) for weight management in December 2024 via Technology Appraisal TA1026. However, NHS England has implemented a phased rollout rather than immediate universal access — reflecting both the capacity of specialist services and the cost to the NHS of treating all eligible patients simultaneously.
NHS Cohort 1 — Currently Active
To qualify for NHS primary care access to Mounjaro under Cohort 1, you must meet ALL of:
- BMI of 40 kg/m² or above (37.5 for South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds)
- At least FOUR of the following five long-term conditions: type 2 diabetes · hypertension · dyslipidaemia · established cardiovascular disease · obstructive sleep apnoea
- Your GP practice must have opted in to the QOF Mounjaro pathway — not all practices have done so
NHS Cohort 2 — Active from 23 June 2026 ⭐ NEW
| Cohort | Start date | BMI threshold | Conditions required | Status |
|---|---|---|---|---|
| Cohort 1 | March 2025 | 40+ (37.5+ ethnic) | 4 of 5 qualifying conditions | ✅ Active |
| Cohort 2 | 23 June 2026 | 35–39.9 (32.5–37.4 ethnic) | 4 of 5 qualifying conditions | ✅ Active from 23 June 2026 |
| Cohort 3 | April 2027 | 40+ (37.5+ ethnic) | 3 of 5 qualifying conditions | ⏳ Planned — not yet active |
| Cohort 4 | April 2028 (projected) | 35+ (32.5+ ethnic) | 2 of 5 qualifying conditions | ⏳ Projected — subject to review |
The QOF T2D pathway (April 2026)
From April 2026, Mounjaro was incorporated into the NHS General Practice contract’s Quality and Outcomes Framework (QOF) for type 2 diabetes management. This means GP practices that have adopted the pathway can prescribe tirzepatide to T2D patients who meet NICE TA1026 criteria — typically BMI 35+ with T2D and at least one other qualifying condition. Participation is optional for GP practices, so availability varies by location.
NHS Tier 3 specialist weight management services
Mounjaro is also available through NHS Tier 3 specialist weight management services — multidisciplinary team services providing intensive dietary, psychological, and medical support. Waiting times for these services are typically 12–36 months. Eligibility criteria vary by ICB but generally require BMI 35+ with at least one comorbidity. Referral is via your GP.
Contraindications — Who Cannot Take Mounjaro
| Contraindication | Reason | Clinical detail |
|---|---|---|
| Personal or family history of medullary thyroid carcinoma (MTC) | Absolute contraindication — do not prescribe | Tirzepatide has been associated with thyroid C-cell tumours in rodent studies. Not confirmed in humans but the precautionary principle applies. Personal OR family history is a contraindication. |
| Multiple Endocrine Neoplasia syndrome type 2 (MEN2) | Absolute contraindication | MEN2 involves MTC risk — same contraindication as above applies. |
| Active pancreatitis or history of pancreatitis | Strong contraindication — use with extreme caution | GLP-1 receptor agonists may increase pancreatitis risk. Active pancreatitis is an absolute contraindication. History of pancreatitis warrants prescriber discussion before any GLP-1 agent. |
| Pregnancy or planned pregnancy | Absolute contraindication | Tirzepatide is not recommended during pregnancy. Women of childbearing potential should use effective contraception during treatment. If pregnancy occurs, discontinue immediately. |
| Breastfeeding | Contraindicated | It is unknown whether tirzepatide passes into breast milk. Treatment should not be used while breastfeeding. |
| Severe renal impairment (eGFR <15) or end-stage renal disease | Use with caution — limited data | No dose adjustment required in mild/moderate renal impairment. Severe impairment has limited data — prescriber judgement required. |
| Gastroparesis or severe GI motility disorder | Relative contraindication | Tirzepatide slows gastric emptying further — may significantly worsen gastroparesis symptoms. |
| Under 18 years of age | Not licensed in the UK for under-18s | MHRA licence covers adults only. Not prescribed by Slinic for patients under 18. |
Mounjaro for Type 2 Diabetes — Eligibility
Mounjaro has two separate UK licences: one for type 2 diabetes management (MHRA approved 2023) and one for weight management (MHRA approved 2024). For T2D patients, eligibility differs from the weight management route:
NHS T2D eligibility (NICE criteria)
NICE recommends tirzepatide for T2D when:
- Three antidiabetic medications have not provided adequate HbA1c control, or cannot be tolerated
- BMI is 35 kg/m² or above (32.5 with ethnic adjustment)
- At least one other significant obesity-related comorbidity is present
Private T2D prescribing at Slinic
For T2D patients seeking Mounjaro privately, Slinic prescribes within the MHRA licence and NICE guidance framework. T2D patients with BMI 27+ and at least one additional qualifying condition are typically eligible. Your HbA1c, current medications, and diabetes management history are reviewed at assessment. Coordination with your GP on insulin and sulphonylurea dose adjustments is essential — your Slinic prescriber provides guidance on this.
Check Your Eligibility at Slinic — 2 Minutes, Free
Named prescriber review · Same working day · BMI 30+ or 27+ with a qualifying condition · GPhC No. 1033729
What Happens If You Don’t Currently Qualify
If your BMI is 27–29.9 without a qualifying condition
You do not currently meet private prescribing criteria for Mounjaro or Wegovy. This is not arbitrary — the clinical evidence for these medications is strongest in patients with BMI 30+ or with weight-related comorbidity. Options include lifestyle intervention, dietary support, and reassessment when your situation changes.
If you meet private criteria but not NHS criteria
The vast majority of patients who are eligible for private Mounjaro do not yet meet NHS primary care criteria. This is because NHS commissioning is significantly more restrictive than NICE’s clinical guidance — by design, to manage capacity. Private prescribing at Slinic provides immediate access from £139/month with no waiting list and no GP referral required.
If your GP practice has not adopted the QOF pathway
Participation in the QOF Mounjaro pathway is optional for GP practices. If your GP practice has not adopted it, you cannot access NHS primary care Mounjaro through that practice — even if you meet the clinical criteria. Options: ask your GP when they plan to adopt the pathway, ask to be referred to an NHS Tier 3 service, or access privately at Slinic.
Wegovy Eligibility vs Mounjaro Eligibility — The Key Differences
| Factor | Mounjaro (tirzepatide) | Wegovy (semaglutide) |
|---|---|---|
| Private BMI threshold | 30+ (or 27+ with condition) | 30+ (or 27+ with condition) — same |
| NHS primary care availability | QOF pathway — GP practice must opt in · Cohorts 1 and 2 active | Cardiovascular pathway (SELECT basis): BMI 27+ with established CVD, no T2D — approved April 2026 |
| Weight loss evidence | 22.5% average at 15mg (SURMOUNT-1) | 15% average at 2.4mg (STEP 1) |
| Cardiovascular approval | Not yet NHS-approved for CVD primary indication (data awaited) | NICE approved April 2026 for BMI 27+ with established CVD — no T2D requirement |
| Slinic price from | £139 (2.5mg) | £99.99 (0.25mg) |
| Best for | Maximum weight loss · T2D patients · Those with multiple comorbidities | Patients with CVD on NHS pathway · Budget-conscious patients · Lower starting BMI |
Frequently Asked Questions
What is the minimum BMI for Mounjaro in the UK?
For private prescribing: BMI 30 or above (no conditions required), or BMI 27–29.9 with at least one qualifying condition (T2D, hypertension, dyslipidaemia, CVD, or sleep apnoea). For NHS primary care (Cohort 1): BMI 40 or above plus at least four qualifying conditions. For NHS Cohort 2 (from 23 June 2026): BMI 35–39.9 plus at least four qualifying conditions. All BMI thresholds are reduced by 2.5 for South Asian, Chinese, other Asian, Middle Eastern, Black African, and African-Caribbean backgrounds.
Can I get Mounjaro on the NHS in 2026?
Yes, through two routes. First, NHS primary care via the QOF Mounjaro pathway — your GP practice must have adopted this pathway. Cohort 1 (BMI 40+ and 4 qualifying conditions) is active. Cohort 2 (BMI 35–39.9 and 4 qualifying conditions) launched 23 June 2026. Second, NHS Tier 3 specialist weight management services — referral via GP, typically 12–36 month wait. Many patients who meet clinical criteria cannot access NHS Mounjaro due to GP practice non-adoption of the QOF pathway and opt for private treatment.
Does having type 2 diabetes help me qualify for Mounjaro?
Yes — significantly. T2D is one of the five qualifying conditions for NHS primary care access and is the most commonly cited qualifying condition. For private prescribing, T2D at BMI 27+ qualifies you for Mounjaro. Additionally, Mounjaro is licensed for T2D management in its own right (not just weight management) — meaning it can be prescribed for your diabetes even if your BMI does not meet the weight management threshold, subject to clinical assessment.
What is the ethnic BMI adjustment for Mounjaro?
For individuals from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds, all BMI thresholds are reduced by 2.5 kg/m². This means: private eligibility threshold reduces from 30 to 27.5 (no conditions) and from 27 to 24.5 (with condition). NHS Cohort 1 reduces from 40 to 37.5. NHS Cohort 2 reduces from 35 to 32.5. This reflects the higher cardiometabolic risk at lower BMI in these populations, as recommended by NICE and the WHO.
What stops me from getting Mounjaro — the main contraindications?
The absolute contraindications are: personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN2), active pancreatitis or significant pancreatitis history, pregnancy or planned pregnancy, and breastfeeding. Additional cautions include: severe renal impairment (eGFR <15), gastroparesis, severe GI motility disorders, and age under 18. Slinic’s prescribers screen for all contraindications at every assessment — full medical history required before prescribing.
How long does it take to get Mounjaro privately at Slinic?
The typical pathway at Slinic: complete the free 2-minute assessment (slinic.co.uk/consultation) → named prescriber reviews same working day → if approved, medication dispatched within 24 hours → next-day tracked cold-chain delivery to your UK address. From assessment to medication in hand: typically 48 hours. No GP referral needed, no waiting list, no subscription commitment.
Official Eligibility and Regulatory References
- NICE TA1026 — Tirzepatide for managing overweight and obesity (December 2024 / updated 2025)
- NHS England — Weight management injections: eligibility and rollout
- Mounjaro Summary of Product Characteristics — eMC (current version)
- GPhC Register — Slinic verification (No. 1033729)
- MHRA — Mounjaro authorisation and counterfeit guidance
Related Treatment Guides
NHS Weight Loss Injections 2026All 3 NHS routes, waiting times, April 2026 changes
Mounjaro Before and After UKClinical trial results, month-by-month timeline
Cheapest Mounjaro UK 2026Full price comparison — all major providers
Mounjaro Dosing ScheduleFull titration guide — ranked #1 UK
Mounjaro vs Wegovy UK 2026SURMOUNT-5 head-to-head results
Eligible? Start Mounjaro at Slinic — No Waiting List, From £139
GPhC No. 1033729 · NHS-contracted · SCOPE Obesity Accredited · LegitScript Certified · Fixed 2026 prices · No subscription
- ✅ Private eligibility: BMI 30+ or 27+ with qualifying condition — assessed same working day
- ✅ Mounjaro 2.5mg £139 → 15mg £285 · all doses dispatched within 24 hours
- ✅ Free starter pack · Free monthly clinical check-ins · £4.99 next-day cold-chain delivery
- ✅ No subscription · No minimum term · Authorised Eli Lilly UK supply chain only
